Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes
- 1 March 2004
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 47 (3) , 555-558
- https://doi.org/10.1007/s00125-003-1323-1
Abstract
Aims/hypothesis The Pro12Ala polymorphism of peroxisome proliferator-activated receptor (PPAR)γ has been consistently associated with Type 2 diabetes. The rare Ala12 variant is estimated to reduce the risk of developing Type 2 diabetes by 20 percent. This variant is in linkage disequilibrium with another common variant, T1431. Both have opposing associations with body weight. We therefore examined the association of specific haplotypes marked by these two variants with susceptibility to Type 2 diabetes. Methods We determined the PPARG genotype of a large Scottish cohort of Type 2 diabetic patients (n=1997) and compared allele frequencies with a cohort of local children (n=2444) and a middle-aged, population-based cohort from Scotland (n=1061). Results Frequency of the Ala12 allele was slightly lower in the Type 2 diabetic cohort than in the children [odds ratio (OR)=0.91, p=0.1]. In contrast, the Ala12 variant was under-represented in the Type 2 diabetic population when compared with similarly aged non-diabetic adults (OR=0.74, p=0.0006). When the Ala12 variant was on a haplotype not bearing the 1431T variant, it conferred greater protection (OR=0.66, p=0.003). However, when it was present in haplotypes containing the 1431T variant (70% of Ala12 carriers), this protection was absent (OR=0.99, p=0.94). Conclusions/interpretation We replicated the finding that the Ala12 variant of PPARγ affords protection from Type 2 diabetes, and suggest that this protection is modulated by additional common variation at the PPARG locus.Keywords
This publication has 12 references indexed in Scilit:
- Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/bgene polymorphisms are associated with essential hypertension.Published by Rockefeller University Press ,2003
- Peroxisome proliferator-activated receptor-??Pro12Ala polymorphism and the association with blood pressure in type 2 diabetesJournal Of Hypertension, 2003
- Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are associated with essential hypertensionJournal Of Hypertension, 2003
- Alanine for Proline Substitution in the Peroxisome Proliferator–Activated Receptor Gamma-2 (PPARG2) Gene and the Risk of Incident Myocardial InfarctionArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Peroxisome proliferator-activated receptor-gammaPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg Hypertension and Diabetes Project.Published by Rockefeller University Press ,2003
- Testing for Population Subdivision and Association in Four Case-Control StudiesAmerican Journal of Human Genetics, 2002
- Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) gene in relation to insulin sensitivity among glucose tolerant CaucasiansDiabetologia, 2001
- Evidence for Gene-Nutrient Interaction at the PPARγ LocusDiabetes, 2001
- Prediction of Osteoporotic Fractures by Bone Densitometry and COLIA1 Genotyping: A Prospective, Population-Based Study in Men and WomenOsteoporosis International, 2001
- The diabetes audit and research in Tayside Scotland (darts) study: electronic record linkage to create a diabetes registerBMJ, 1997